NASDAQ:IMCR

Immunocore Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy IMCR

*Your capital is at risk

$29.20

-0.150 (-0.511%)

At Close: Jun 23, 2026

Immunocore Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 31.22. In total, the insiders bought 3.66M and sold 414.1K IMCR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	31.22
● Buy	3.66M shares
● Sell	414.1K shares
74% Buy Activity Weak Negative Correlation
Buy Signal Medium Confidence Feb 17, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 31.22. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Bell John Irving Director	Director	27 492 Value: $784.1K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Herbst Roy Steven Director	Director	27 492 Value: $784.1K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Kaul Siddharth Director	Director	27 492 Value: $784.1K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Pao William Director	Director	27 492 Value: $784.1K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Peterson Kristine Director	Director	27 492 Value: $784.1K
May 27, 2026 Buy	Share Option (Right to Buy) A-Award	Ratcliffe Peter John Director	Director	27 492 Value: $784.1K
Feb 18, 2026 Sell	Ordinary Shares S-Sale	Berman David M Head Of R&d	Officer	5 965 Value: $193.0K
Feb 18, 2026 Sell	Ordinary Shares S-Sale	St Leger Tina Amber Chief Hr Officer	Officer	1 000 Value: $32.4K
Feb 18, 2026 Sell	Ordinary Shares S-Sale	Goll John SVP, Finance & Cao	Officer	698 Value: $22.6K
Feb 18, 2026 Sell	Ordinary Shares S-Sale	Jallal Bahija Chief Executive Officer	CEO / President	11 474 Value: $371.2K
Feb 17, 2026 Buy	Ordinary Shares M-Exempt	Berman David M Head Of R&d	Officer	11 824 Value: $382.9K
Feb 17, 2026 Buy	Restricted Share Units M-Exempt	Berman David M Head Of R&d	Officer	11 824 Value: $382.9K
Feb 17, 2026 Buy	Ordinary Shares M-Exempt	St Leger Tina Amber Chief Hr Officer	Officer	2 119 Value: $68.6K
Feb 17, 2026 Buy	Restricted Share Units M-Exempt	St Leger Tina Amber Chief Hr Officer	Officer	2 119 Value: $68.6K
Feb 17, 2026 Buy	Ordinary Shares M-Exempt	Goll John SVP, Finance & Cao	Officer	1 351 Value: $43.7K
Feb 17, 2026 Buy	Restricted Share Units M-Exempt	Goll John SVP, Finance & Cao	Officer	1 351 Value: $43.7K
Feb 17, 2026 Buy	Restricted Share Units A-Award	Goll John SVP, Finance & Cao	Officer	7 411 Value: $240.0K
Feb 17, 2026 Buy	Employee Share Option (Right to Buy) A-Award	Goll John SVP, Finance & Cao	Officer	21 252 Value: $688.1K
Feb 17, 2026 Buy	Ordinary Shares M-Exempt	Jallal Bahija Chief Executive Officer	CEO / President	23 817 Value: $771.2K
Feb 17, 2026 Buy	Restricted Share Units M-Exempt	Jallal Bahija Chief Executive Officer	CEO / President	23 817 Value: $771.2K
Feb 17, 2026 Buy	Restricted Share Units A-Award	Jallal Bahija Chief Executive Officer	CEO / President	88 573 Value: $2.87M
Feb 17, 2026 Buy	Employee Share Option (Right to Buy) A-Award	Jallal Bahija Chief Executive Officer	CEO / President	395 066 Value: $12.8M
Feb 17, 2026 Buy	Restricted Share Units A-Award	Coy Travis Alan Chief Financial Officer	C-Suite Officer	33 353 Value: $1.08M
Feb 17, 2026 Buy	Employee Share Option (Right to Buy) A-Award	Coy Travis Alan Chief Financial Officer	C-Suite Officer	95 637 Value: $3.10M
Dec 05, 2025 Sell	Ordinary Shares S-Sale	Berman David M Head Of R&d	Officer	572 Value: $23.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNOCORE HOLDINGS PLC

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (N...

Read Full Profile Here